Referred to as HiberTherapeutics™, the Company’s new pharmacological approach to cardiovascular and related drug development and other treatments has been developed from natural hibernation mechanisms studied by leading international scientists and medical practitioners and demonstrated in pre-clinical and clinical trials.

The HiberTherapeutics approach is strongly supported by a patented technology platform owned by Hibernation Therapeutics.